2011
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence
Soyka M, Kranzler HR, van den Brink W, Krystal J, Möller HJ, Kasper S, Treatment G. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. The World Journal Of Biological Psychiatry 2011, 12: 160-187. PMID: 21486104, DOI: 10.3109/15622975.2011.561872.Peer-Reviewed Original ResearchMeSH KeywordsAdultAryl Hydrocarbon HydroxylasesBuprenorphineCytochrome P-450 CYP2B6Cytochrome P-450 CYP2D6Drug Therapy, CombinationEvidence-Based MedicineGenetic VariationHumansMethadoneNarcotic AntagonistsNarcoticsOpiate Substitution TreatmentOpioid-Related DisordersOxidoreductases, N-DemethylatingPsychotherapyReceptors, OpioidSocial SupportStandard of CareSubstance Withdrawal SyndromeConceptsOpioid dependenceOpioid abusePractice guidelinesEvidence-based practice guidelinesBiological Psychiatry (WFSBP) GuidelinesOpioid agonist methadoneSecond-line medicationsNational treatment guidelinesNumber of medicationsEfficacy of methadoneOpioid use disorderEvidence-based guidelinesRandomized clinical trialsCombination of buprenorphineWorld FederationInternational task forceStrength of evidenceOpioid withdrawalAdjunctive medicationsOpioid maintenanceTreatment guidelinesTask ForceCochrane LibraryPharmacological treatmentClinical trials
1994
SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine
van Dyck C, Rosen M, Thomas H, McMahon T, Wallace E, O'Connor P, Sullivan M, Krystal J, Hoffer P, Woods S, Kosten T. SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry Research 1994, 55: 181-191. PMID: 7701033, DOI: 10.1016/0925-4927(94)90013-2.Peer-Reviewed Original ResearchConceptsRegional cerebral blood flowRegional cerebral blood flow alterationsCerebral blood flow alterationsHexamethyl propylene amine oximeOpiate-induced analgesiaBlood flow alterationsSeverity of withdrawalCerebral blood flowOpiate-dependent patientsAnterior cingulate regionsAnterior cingulate cortexSingle photon emissionPlacebo administrationAmine oximeOpiate withdrawalRCBF ratiosWithdrawal severityBlood flowCingulate cortexCingulate regionsSignificant negative correlationBuprenorphineNaltrexonePlaceboPatients
1990
Opioid antagonist challenges in buprenorphine maintained patients
Kosten T, Krystal J, Charney D, Price L, Morgan C, Kleber H. Opioid antagonist challenges in buprenorphine maintained patients. Drug And Alcohol Dependence 1990, 25: 73-78. PMID: 2323312, DOI: 10.1016/0376-8716(90)90144-4.Peer-Reviewed Original ResearchConceptsSublingual buprenorphine treatmentBlood pressure increaseDouble-blind placeboOpioid withdrawal symptomsBlind placeboIntravenous naloxoneNaltrexone challengeOral naltrexoneLast doseBlood pressureBuprenorphine treatmentPlacebo substitutionMHPG levelsWithdrawal symptomsPlacebo challengeSignificant symptomsAntagonist challengeBuprenorphinePatientsPlaceboNaloxoneSymptomsNaltrexoneDoseMonths
1989
Rapid detoxification from opioid dependence
Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD. Rapid detoxification from opioid dependence. American Journal Of Psychiatry 1989, 146: 1349a-1349. PMID: 2675644, DOI: 10.1176/ajp.146.10.1349a.Peer-Reviewed Original Research